$LPCN
Lipocine Inc. Stock $lpcn

$lpcn Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-K Financial Statement

#000114420417012930 Filed on March 06, 2017

Income Statement

Concept	2017 Q1	2016 Q4	2015 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.830M	$1.340M	$1.930M
YoY Change	-58.41%	-30.57%	64.96%
% of Gross Profit
Research & Development	$3.084M	$1.330M	$2.770M
YoY Change	15.35%	-51.99%	-4.15%
% of Gross Profit
Depreciation & Amortization	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%
% of Gross Profit
Operating Expenses	$4.909M	$2.680M	$4.700M
YoY Change	-30.57%	-42.98%	15.76%
Operating Profit	-$4.909M	-$3.015M	-$4.696M
YoY Change	-30.57%	-35.8%
Interest Expense	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$48.36K	$50.00K	$60.00K
YoY Change	-19.41%	-16.67%	200.0%
Pretax Income	-$4.861M	-$2.970M	-$4.630M
YoY Change	-30.65%	-35.85%	14.6%
Income Tax	$700.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.861M	-$2.966M	-$4.634M
YoY Change	-30.65%	-35.98%	14.7%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.26	-$0.16	-$0.25
Diluted Earnings Per Share	-$0.26	-$0.16	-$0.25
COMMON SHARES
Basic Shares Outstanding	18.59M shares	18.26M shares	18.25M shares
Diluted Shares Outstanding	18.71M shares

Balance Sheet

Concept	2017 Q1	2016 Q4	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.80M	$26.84M	$44.38M
YoY Change	-29.86%	-39.52%	60.39%
Cash & Equivalents	$6.937M	$5.561M	$20.01M
Short-Term Investments	$19.86M	$21.28M	$24.38M
Other Short-Term Assets	$260.0K	$330.0K	$350.0K
YoY Change	-3.7%	-5.71%	52.17%
Inventory
Prepaid Expenses
Receivables	$40.00K	$40.00K	$140.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$27.10M	$27.21M	$44.88M
YoY Change	-29.87%	-39.37%	60.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$100.0K	$100.0K	$75.75K
YoY Change	-9.09%	32.01%	2.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$400.0K
YoY Change		-100.0%
Other Assets	$30.00K	$30.75K	$23.75K
YoY Change	50.0%	29.47%	0.0%
Total Long-Term Assets	$120.0K	$131.2K	$499.8K
YoY Change	-7.69%	-73.74%	412.39%
TOTAL ASSETS
Total Short-Term Assets	$27.10M	$27.21M	$44.88M
Total Long-Term Assets	$120.0K	$131.2K	$499.8K
Total Assets	$27.22M	$27.34M	$45.38M
YoY Change	-29.79%	-39.75%	62.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$850.0K	$250.0K	$507.1K
YoY Change	-21.3%	-50.7%	65.56%
Accrued Expenses	$1.491M	$1.080M	$2.885M
YoY Change	-22.32%	-62.55%	117.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.340M	$1.330M	$3.392M
YoY Change	-21.74%	-60.79%	107.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.340M	$1.330M	$3.392M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.340M	$1.330M	$3.392M
YoY Change	-21.74%	-60.79%	107.64%
SHAREHOLDERS EQUITY
Retained Earnings			-$86.45M
YoY Change			26.68%
Common Stock		$1.846K	$1.825K
YoY Change		1.15%	42.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$40.71K
YoY Change			0.0%
Treasury Stock Shares	5.710K shares	5.710K shares	5.710K shares
Shareholders Equity	$24.88M	$26.02M	$41.99M
YoY Change
Total Liabilities & Shareholders Equity	$27.22M	$27.34M	$45.38M
YoY Change	-29.79%	-39.75%	62.1%

Cashflow Statement

Concept	2017 Q1	2016 Q4	2015 Q4
OPERATING ACTIVITIES
Net Income	-$4.861M	-$2.966M	-$4.634M
YoY Change	-30.65%	-35.98%	14.7%
Depreciation, Depletion And Amortization	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%
Cash From Operating Activities	-$3.139M	-$2.550M	-$2.920M
YoY Change	-51.79%	-12.67%	-20.87%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$1.430M	$2.830M	-$1.010M
YoY Change	130.65%	-380.2%
Cash From Investing Activities	$1.428M	$2.830M	-$1.010M
YoY Change	146.19%	-380.2%	2425.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.698M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.087M	580.0K	0.000
YoY Change	10188.83%		-100.0%
NET CHANGE
Cash From Operating Activities	-$3.139M	-2.550M	-2.920M
Cash From Investing Activities	$1.428M	2.830M	-1.010M
Cash From Financing Activities	$3.087M	580.0K	0.000
Net Change In Cash	$1.376M	860.0K	-3.930M
YoY Change	-123.32%	-121.88%	-2.0%
FREE CASH FLOW
Cash From Operating Activities	-$3.139M	-$2.550M	-$2.920M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$3.139M	-$2.550M	-$2.920M
YoY Change	-52.07%	-12.67%	-20.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	lpcn	Vesting Of Restricted Stock Awards Value VestingOfRestrictedStockAwardsValue	0	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1080254	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1892835	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-18970756	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	752	USD
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18258149	shares
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.04
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18258149	shares
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18947101	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	44823747	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1150418	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	56776	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	276994	USD
CY2015	lpcn	Vesting Of Restricted Stock Awards Value VestingOfRestrictedStockAwardsValue	0	USD
CY2014	lpcn	Vesting Of Restricted Stock Units Value VestingOfRestrictedStockUnitsValue	0	USD
CY2014	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	40712	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	26359970	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	32439313	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14620	USD
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	26721	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1892835	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1150418	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-540118	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	120248	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-449562	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	200791	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1070502	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1557538	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-17304163	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15356304	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59608	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28689	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-38361	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-25018399	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16064	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	276994	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-255119	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	32716307	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-17597643	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7658396	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45263698	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27666055	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	271183	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015	us-gaap	Payments For Proceeds From Other Deposits PaymentsForProceedsFromOtherDeposits	0	USD
CY2014	us-gaap	Payments For Proceeds From Other Deposits PaymentsForProceedsFromOtherDeposits	-21247	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32439313	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2014	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	40712	USD
CY2015	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	144536	USD
CY2014	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	USD
CY2015	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	25789710	USD
CY2014	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
CY2014	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	0	USD
CY2015	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	-32900	USD
CY2015	us-gaap	Accretion Expense AccretionExpense	181390	USD
CY2014	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	800000	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	31960	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	2372615	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-20612	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-261152	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1804540	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18281938	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59650	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3229125	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	605870	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0176	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8426	pure
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3900000	USD
CY2016	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	605870	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14446943	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016	us-gaap	Payments For Proceeds From Other Deposits PaymentsForProceedsFromOtherDeposits	7000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2016	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-105593	USD
CY2016	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	25272225	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8139	pure
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-18971508	USD
CY2016	us-gaap	Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax	24407	USD
CY2016	us-gaap	Accretion Expense AccretionExpense	224482	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	28568000	USD
CY2016Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	2921000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0163	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0175	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7630	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.06
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18208378	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20372676	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-18208378	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-20372676	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18971508	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	21288063	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	21279570	USD
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1048932	USD
CY2015Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1041735	USD
CY2016Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	103857	USD
CY2015Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	51404	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1092710	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1060750	USD
CY2016Q4	lpcn	Computer Equipment And Capitalized Computer Software Gross ComputerEquipmentAndCapitalizedComputerSoftwareGross	43361	USD
CY2015Q4	lpcn	Computer Equipment And Capitalized Computer Software Gross ComputerEquipmentAndCapitalizedComputerSoftwareGross	43361	USD
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6190781	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6926642	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6691992	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7748579	USD
CY2015	lpcn	Income Tax Rate Reconciliation Loss Of Tax Attributes Due To Change In Ownership IncomeTaxRateReconciliationLossOfTaxAttributesDueToChangeInOwnership	0	USD
CY2014	lpcn	Income Tax Rate Reconciliation Loss Of Tax Attributes Due To Change In Ownership IncomeTaxRateReconciliationLossOfTaxAttributesDueToChangeInOwnership	-127572	USD
CY2015	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	4697	USD
CY2014	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	3792	USD
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	132	USD
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	132	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	102221	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	45097	USD
CY2015	lpcn	Income Tax Reconciliation Orphan Drug Tax Credits IncomeTaxReconciliationOrphanDrugTaxCredits	155452	USD
CY2014	lpcn	Income Tax Reconciliation Orphan Drug Tax Credits IncomeTaxReconciliationOrphanDrugTaxCredits	0	USD
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	452609	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	743186	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6450075	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6709591	USD
CY2016	lpcn	Income Tax Rate Reconciliation Loss Of Tax Attributes Due To Change In Ownership IncomeTaxRateReconciliationLossOfTaxAttributesDueToChangeInOwnership	0	USD
CY2016	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	6347	USD
CY2016	lpcn	Income Tax Reconciliation Orphan Drug Tax Credits IncomeTaxReconciliationOrphanDrugTaxCredits	127641	USD
CY2016	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	337968	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1924260	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1713608	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	30700358	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	23677332	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	69112	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	59472	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2465893	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2052662	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	70231	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	215638	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35909039	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28204501	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35904927	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28200857	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4112	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3644	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4112	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3644	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	496	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	200002	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4112	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3644	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	lpcn	Deferred Tax Assets Orphan Drug Tax Credit DeferredTaxAssetsOrphanDrugTaxCredit	679185	USD
CY2015Q4	lpcn	Deferred Tax Assets Orphan Drug Tax Credit DeferredTaxAssetsOrphanDrugTaxCredit	485789	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7700000	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7300000	USD
CY2016	lpcn	Operating Loss Carry Forwards Limitations On Use Amount OperatingLossCarryForwardsLimitationsOnUseAmount	1100000	USD
CY2016	lpcn	Operating Loss Carry Forwards Preownership Change Amount OperatingLossCarryForwardsPreownershipChangeAmount	20200000	USD
CY2016	lpcn	Operating Loss Forgive Pre Ownership Change Amount OperatingLossForgivePreOwnershipChangeAmount	5500000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	446022	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	387119	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	58903	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	327000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	295000	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	63.96
CY2016	lpcn	Class Of Warrant Or Right Redemption Price Of Warrants Or Rights ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights	0.001
CY2016	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2018-11-12
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	658000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	87000	USD
CY2016	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	74000	USD
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	48000	USD
CY2013Q3	lpcn	Maximum Proceeds From Affiliates Under License Agreement MaximumProceedsFromAffiliatesUnderLicenseAgreement	10000000	USD
CY2013Q3	lpcn	Percentage Of Fee To Be Received PercentageOfFeeToBeReceived	0.2	pure
CY2013Q3	lpcn	Service Fee ServiceFee	230	USD
CY2015	lpcn	Proceeds From Reimbursement ProceedsFromReimbursement	61000	USD
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Entity Registrant Name EntityRegistrantName	Lipocine Inc.
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001535955
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q2	dei	Entity Public Float EntityPublicFloat	51800000	USD
CY2016	dei	Trading Symbol TradingSymbol	LPCN
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18594889	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18462325	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18250456	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18456615	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18244746	shares
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5710	shares
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5710	shares
CY2016	us-gaap	Restructuring Charges RestructuringCharges	728635	USD
CY2015	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2014	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2372615	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	605870	USD
CY2016	lpcn	Vesting Of Restricted Stock Awards Value VestingOfRestrictedStockAwardsValue	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	21288063	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8493	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	594	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	21279570	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	24808320	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	33494	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	24775420	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	21288063	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21279570	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	28600000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	800000	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1196150	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1136500	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	374000	USD
CY2016Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	78000000	USD
CY2016Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	1600000	USD
CY2016	lpcn	Tax Credit Carryforward Preownership Change Amount TaxCreditCarryforwardPreownershipChangeAmount	1200000	USD
CY2016	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2015	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2014	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2016	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	752	USD
CY2015	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	200	USD
CY2014	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	200	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7070404	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5815120	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3286220	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-3015090	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-7009445	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-5760111	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-3235485	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-2966467	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2974239	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4277743	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6433988	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4696098	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2372615	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1150418	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1892835	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-2955806	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-4246446	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-6372428	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-4633698	USD
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M2D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M13D
CY2016	lpcn	Proceeds From Reimbursement ProceedsFromReimbursement	3000	USD
CY2014	lpcn	Proceeds From Reimbursement ProceedsFromReimbursement	0	USD
CY2016	lpcn	Description Of Terms Of Service Agreement DescriptionOfTermsOfServiceAgreement	Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain employees to Spriaso for a period of 18 months which expired
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	128000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	24200147	USD
CY2015Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	24903325	USD
CY2015Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	128000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.60
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.45
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	216000	USD
CY2015Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2016	us-gaap	Payments For Restructuring PaymentsForRestructuring	437796	USD
CY2016	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	51266	USD
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	239573	USD
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.5pt"> </div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 24.5pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="33"> <div><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 24.5pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="33"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> (a)</font></i></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Use of Estimates</font></i></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.5pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: black; FONT-SIZE: 10pt">  </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0in 0.75in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: black; FONT-SIZE: 10pt"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include those related to revenue recognition; stock-based compensation; valuation of deferred taxes; income tax uncertainties; and the useful lives of property and equipment.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD

Files In Submission

Name	View Source	Status
0001144204-17-012930-index-headers.html	Edgar Link	pending
0001144204-17-012930-index.html	Edgar Link	pending
0001144204-17-012930.txt	Edgar Link	pending
0001144204-17-012930-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lpcn-20161231.xml	Edgar Link	completed
lpcn-20161231.xsd	Edgar Link	pending
lpcn-20161231_cal.xml	Edgar Link	unprocessable
lpcn-20161231_def.xml	Edgar Link	unprocessable
lpcn-20161231_lab.xml	Edgar Link	unprocessable
lpcn-20161231_pre.xml	Edgar Link	unprocessable
pg46img1_10k.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v460000_10k.htm	Edgar Link	pending
v460000_ex10-22.htm	Edgar Link	pending
v460000_ex10-23.htm	Edgar Link	pending
v460000_ex10-24.htm	Edgar Link	pending
v460000_ex21-1.htm	Edgar Link	pending
v460000_ex23-1.htm	Edgar Link	pending
v460000_ex31-1.htm	Edgar Link	pending
v460000_ex31-2.htm	Edgar Link	pending
v460000_ex32-1.htm	Edgar Link	pending
v460000_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LPCN
Lipocine Inc. Stock $lpcn

2017 Q1 Form 10-K Financial Statement

#000114420417012930 Filed on March 06, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LPCN Lipocine Inc. Stock $lpcn

2017 Q1 Form 10-K Financial Statement

#000114420417012930 Filed on March 06, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LPCN
Lipocine Inc. Stock $lpcn